USP 71125-38-7 Meloxicam Powder C14H13N3O4S2 99% Purity

Factory Direct Supply 71125-38-7 Meloxicam with High Purity in Stock

Meloxicam, a non-steroidal anti-inflammatory agent, has been reported to inhibit the inducible isoform of Cox-2. Meloxicam is an inhibitor selective for Cox-2 (IC50 of 4.7 μM) over Cox-1 (IC50 of 36.6 μM). Studies suggest that Meloxicam is Cox-2 preferential,therefore it will probably not display a lower gastrointestinal toxicity than non-selective anti-inflammatory agents. This compound has been shown to also inhibit prostanoid synthesis in inflammatory cells. Additionally, Meloxicam has demonstrated the ability to non-competitively inhibit erythrocyte PGD (6-phosphogluconate dehydrogenase) activity in vitro.

Meloxicam is a non-steroidal antipyretic and analgesic anti-inflammatory drug, not a hormonal drug. It has strong anti-inflammatory, analgesic and antipyretic effects, and can selectively inhibit cyclooxygenase-2 (COX-2). Activity, thereby blocking prostaglandin synthesis, inhibiting prostaglandin biosynthesis at the Chemicalbook site of the inflammatory department is stronger than prostaglandin biosynthesis in the gastric mucosa or kidney, and is more safe than other NSAIDs. It is mainly used to relieve the symptoms of osteoarthritis, painful osteoarthritis, rheumatoid arthritis and joint spondylitis.For rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, soft tissue injury and pain. The overview, pharmacological effects, pharmacokinetics, synthesis, and use of meloxicam were edited by Shi Yan of Chemicalbook. (2015-11-23 Chemicalbook)
Adverse reactions
Indigestion, abdominal pain, nausea, diarrhea, elevated liver enzymes, dizziness, headache, rash, and anemia can occur. Occasionally edema, elevated blood pressure, mild serum creatinine or urea nitrogen abnormality, acute renal failure, gastric ulcer, gastric bleeding, gastric perforation, leukocytes, and thrombocytopenia.

Hot products